Trial Profile
Reduction of Th17+ Lymphocytes in patients with SAPHO syndrome and psoriatic arthritis before and under treatment with secukinumab.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2017
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Acquired hyperostosis syndrome; Psoriatic arthritis
- Focus Pharmacodynamics
- 05 Jul 2017 New trial record
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism